Future Tech: Almost Here, Round-the-corner Future Technology Podcast

Dr. Christian Regenbrecht, shareholder, CEO, of CELLphenomics, provides an overview of his company’s important work that could assist researchers as they strive to develop new drugs to treat disease. Regenbrecht studied biology and philosophy at the University of Bonn, and continued his postdoc with noted scientist, Hans Lehrach, at the Max Planck Institute for Molecular Genomics in Berlin. Regenbrecht has focused some of his time on improved patient-derived in vitro models, culture technologies, and preclinical efficacy studies. Regenbrecht discusses his extensive work and the innovations that are happening at CELLphenomics. With greater than 400 proprietary patient-derived 3D (PD3D®) cell cultures, CELLphenomics can offer researchers an opportunity to test compounds with a comprehensive screening approach in an, up to, 384 well format. In simplest terms, patient-derived cell cultures are essentially novel multicellular systems newly isolated from primary organs through mechanical and enzymatic dissociatio